US5693343A
(en)
|
1984-03-16 |
1997-12-02 |
The United States Of America As Represented By The Secretary Of The Army |
Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
|
US20030161889A1
(en)
*
|
1984-03-16 |
2003-08-28 |
Reid Robert H. |
Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
|
US5417986A
(en)
*
|
1984-03-16 |
1995-05-23 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
|
US6217911B1
(en)
|
1995-05-22 |
2001-04-17 |
The United States Of America As Represented By The Secretary Of The Army |
sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
USRE40786E1
(en)
|
1984-03-16 |
2009-06-23 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
|
US6410056B1
(en)
|
1984-03-16 |
2002-06-25 |
The United States Of America As Represented By The Secretary Of The Army |
Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
|
US5762965A
(en)
*
|
1984-03-16 |
1998-06-09 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccines against intracellular pathogens using antigens encapsulated within biodegradble-biocompatible microspheres
|
GB2209937B
(en)
*
|
1987-09-21 |
1991-07-03 |
Depiopharm S A |
Water insoluble polypeptides
|
US5271945A
(en)
*
|
1988-07-05 |
1993-12-21 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsule for water soluble drug
|
US5444113A
(en)
*
|
1988-08-08 |
1995-08-22 |
Ecopol, Llc |
End use applications of biodegradable polymers
|
US6323307B1
(en)
|
1988-08-08 |
2001-11-27 |
Cargill Dow Polymers, Llc |
Degradation control of environmentally degradable disposable materials
|
US4990336A
(en)
*
|
1989-02-08 |
1991-02-05 |
Biosearch, Inc. |
Sustained release dosage form
|
WO1990013361A1
(fr)
*
|
1989-05-04 |
1990-11-15 |
Southern Research Institute |
Procede ameliore d'encapsulation et produits obtenus
|
CH679207A5
(fr)
*
|
1989-07-28 |
1992-01-15 |
Debiopharm Sa |
|
US5225205A
(en)
*
|
1989-07-28 |
1993-07-06 |
Debiopharm S.A. |
Pharmaceutical composition in the form of microparticles
|
US5439688A
(en)
*
|
1989-07-28 |
1995-08-08 |
Debio Recherche Pharmaceutique S.A. |
Process for preparing a pharmaceutical composition
|
MY107937A
(en)
*
|
1990-02-13 |
1996-06-29 |
Takeda Chemical Industries Ltd |
Prolonged release microcapsules.
|
US5238714A
(en)
*
|
1990-10-02 |
1993-08-24 |
Board Of Regents, The University Of Texas System |
Efficient microcapsule preparation and method of use
|
US5484584A
(en)
*
|
1990-10-02 |
1996-01-16 |
Board Of Regents, The University Of Texas System |
Therapeutic and diagnostic use of modified polymeric microcapsules
|
US5102402A
(en)
|
1991-01-04 |
1992-04-07 |
Medtronic, Inc. |
Releasable coatings on balloon catheters
|
US5153002A
(en)
*
|
1991-03-04 |
1992-10-06 |
University Of Montreal |
Biocompatible gradient controlled release implant
|
AU8303691A
(en)
|
1991-04-24 |
1992-12-21 |
United States Of America, As Represented By The Secretary Of The Army, The |
Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
|
CH683149A5
(fr)
*
|
1991-07-22 |
1994-01-31 |
Debio Rech Pharma Sa |
Procédé pour la préparation de microsphères en matériau polymère biodégradable.
|
US5470582A
(en)
*
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
US6013853A
(en)
*
|
1992-02-14 |
2000-01-11 |
The University Of Texas System |
Continuous release polymeric implant carrier
|
US5876452A
(en)
*
|
1992-02-14 |
1999-03-02 |
Board Of Regents, University Of Texas System |
Biodegradable implant
|
US5912015A
(en)
*
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
ATE154240T1
(de)
*
|
1992-03-12 |
1997-06-15 |
Alkermes Inc |
Acth enthaltende mikrokugeln mit gesteuerter abgabe
|
US5599352A
(en)
*
|
1992-03-19 |
1997-02-04 |
Medtronic, Inc. |
Method of making a drug eluting stent
|
US5571166A
(en)
*
|
1992-03-19 |
1996-11-05 |
Medtronic, Inc. |
Method of making an intraluminal stent
|
US5591224A
(en)
*
|
1992-03-19 |
1997-01-07 |
Medtronic, Inc. |
Bioelastomeric stent
|
US5510077A
(en)
*
|
1992-03-19 |
1996-04-23 |
Dinh; Thomas Q. |
Method of making an intraluminal stent
|
US5716644A
(en)
*
|
1992-06-11 |
1998-02-10 |
Alkermes, Inc. |
Composition for sustained release of non-aggregated erythropoietin
|
US5674534A
(en)
*
|
1992-06-11 |
1997-10-07 |
Alkermes, Inc. |
Composition for sustained release of non-aggregated erythropoietin
|
US5711968A
(en)
*
|
1994-07-25 |
1998-01-27 |
Alkermes Controlled Therapeutics, Inc. |
Composition and method for the controlled release of metal cation-stabilized interferon
|
US20030035845A1
(en)
*
|
1992-06-11 |
2003-02-20 |
Zale Stephen E. |
Composition for sustained release of non-aggregated erythropoietin
|
US6514533B1
(en)
|
1992-06-11 |
2003-02-04 |
Alkermas Controlled Therapeutics, Inc. |
Device for the sustained release of aggregation-stabilized, biologically active agent
|
FR2693905B1
(fr)
*
|
1992-07-27 |
1994-09-02 |
Rhone Merieux |
Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
|
WO1994007469A1
(fr)
*
|
1992-09-25 |
1994-04-14 |
Dynagen, Inc. |
Immunorenforçateur pour liberation differee d'un immunogene
|
EP0674506B1
(fr)
*
|
1992-12-02 |
2000-08-23 |
Alkermes Controlled Therapeutics, Inc. |
Microspheres contenant une hormone de croissance a liberation regulee
|
TW333456B
(en)
*
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
UA61046C2
(en)
*
|
1992-12-07 |
2003-11-17 |
Takeda Chemical Industries Ltd |
Sustained-release preparation and method for its manufacture
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
AU6400194A
(en)
*
|
1993-03-22 |
1994-10-11 |
United States Of America, As Represented By The Secretary Of The Army, The |
Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
|
US5456917A
(en)
*
|
1993-04-12 |
1995-10-10 |
Cambridge Scientific, Inc. |
Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
|
US6939546B2
(en)
|
1993-05-21 |
2005-09-06 |
The United States Of America As Represented By The Secretary Of The Army |
Model for testing immunogenicity of peptides
|
US5603960A
(en)
*
|
1993-05-25 |
1997-02-18 |
O'hagan; Derek T. |
Preparation of microparticles and method of immunization
|
US6080429A
(en)
*
|
1993-10-25 |
2000-06-27 |
Genentech, Inc. |
Method for drying microspheres
|
US5643605A
(en)
*
|
1993-10-25 |
1997-07-01 |
Genentech, Inc. |
Methods and compositions for microencapsulation of adjuvants
|
US6913767B1
(en)
|
1993-10-25 |
2005-07-05 |
Genentech, Inc. |
Compositions for microencapsulation of antigens for use as vaccines
|
SI0729357T1
(en)
*
|
1993-11-19 |
2005-06-30 |
Janssen Pharmaceutica N.V. |
Microencapsulated 1,2-benzazoles
|
AU710504B2
(en)
*
|
1994-03-15 |
1999-09-23 |
Brown University Research Foundation |
Polymeric gene delivery system
|
ES2171186T3
(es)
*
|
1994-04-08 |
2002-09-01 |
Atrix Lab Inc |
Composiciones liquidas de difusion.
|
US6013268A
(en)
|
1994-04-22 |
2000-01-11 |
Corixa Corporation |
Methods for enhancement of protective immune responses
|
US5876735A
(en)
*
|
1994-04-22 |
1999-03-02 |
Corixa Corporation |
Methods for enhancement of protective immune responses
|
US6855331B2
(en)
|
1994-05-16 |
2005-02-15 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
US6447796B1
(en)
|
1994-05-16 |
2002-09-10 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
USRE38827E1
(en)
|
1994-07-27 |
2005-10-11 |
3M Innovative Properties Company |
Adhesive sealant composition
|
US5583114A
(en)
|
1994-07-27 |
1996-12-10 |
Minnesota Mining And Manufacturing Company |
Adhesive sealant composition
|
KR100201352B1
(ko)
*
|
1995-03-16 |
1999-06-15 |
성재갑 |
단일주사 백신 제형
|
US6902743B1
(en)
|
1995-05-22 |
2005-06-07 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
|
US7033608B1
(en)
|
1995-05-22 |
2006-04-25 |
The United States Of America As Represented By The Secretary Of The Army |
“Burst-free” sustained release poly-(lactide/glycolide) microspheres
|
AUPN366795A0
(en)
*
|
1995-06-20 |
1995-07-13 |
Peptide Technology Limited |
Formulation for preventing reproductive function
|
US6265389B1
(en)
|
1995-08-31 |
2001-07-24 |
Alkermes Controlled Therapeutics, Inc. |
Microencapsulation and sustained release of oligonucleotides
|
WO1997007788A2
(fr)
*
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics, Inc. |
Composition se pretant a la liberation prolongee d'un agent
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
CZ300688B6
(cs)
|
1995-09-01 |
2009-07-15 |
Corixa Corporation |
Polypeptid, farmaceutický prostredek a vakcína s jeho obsahem, zpusob prípravy a použití polypeptidu, molekula rekombinantní DNA a její použití, expresní vektor, hostitelská bunka, fúsní porotein a diagnostický kit
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
TW448055B
(en)
*
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
US5942253A
(en)
|
1995-10-12 |
1999-08-24 |
Immunex Corporation |
Prolonged release of GM-CSF
|
AU717113B2
(en)
|
1995-11-09 |
2000-03-16 |
Health Protection Agency |
Microencapsulated DNA for vaccination and gene therapy
|
US6270795B1
(en)
|
1995-11-09 |
2001-08-07 |
Microbiological Research Authority |
Method of making microencapsulated DNA for vaccination and gene therapy
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
CA2192773C
(fr)
|
1995-12-15 |
2008-09-23 |
Hiroaki Okada |
Obtention d'une preparation a liberation prolongee pour injection
|
EP1007080B1
(fr)
*
|
1996-08-30 |
2007-04-18 |
Peptech Limited |
Formulation à libération prolongée des agonistes et analogues peptidiques de GnRH
|
US5968895A
(en)
*
|
1996-12-11 |
1999-10-19 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US20070185032A1
(en)
*
|
1996-12-11 |
2007-08-09 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US6203813B1
(en)
|
1997-01-13 |
2001-03-20 |
Lance L. Gooberman |
Pharmaceutical delivery device and method of preparation therefor
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US6126919A
(en)
*
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
EP0981624A2
(fr)
|
1997-02-12 |
2000-03-01 |
Corixa Corporation |
ANTIGENES $i(LEISHMANIA) UTILISES DANS LE TRAITEMENT ET LE DIAGNOSTIC DE LA LEISHMANIOSE
|
US6261562B1
(en)
|
1997-02-25 |
2001-07-17 |
Corixa Corporation |
Compounds for immunotherapy of prostate cancer and methods for their use
|
ZA982968B
(en)
|
1997-04-09 |
1998-10-27 |
Corixa Corp |
Compositions and methods for the treatment and diagnosis of breast cancer
|
AR012448A1
(es)
*
|
1997-04-18 |
2000-10-18 |
Ipsen Pharma Biotech |
Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
|
US7087713B2
(en)
*
|
2000-02-25 |
2006-08-08 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
EP1042360A2
(fr)
|
1997-12-24 |
2000-10-11 |
Corixa Corporation |
Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
EP2003201A3
(fr)
|
1998-03-18 |
2008-12-31 |
Corixa Corporation |
Composés et méthodes thérapeutiques et diagnostiques du cancer du poumon
|
CA2326598C
(fr)
|
1998-04-07 |
2014-06-10 |
Corixa Corporation |
Proteines hybrides d'antigenes de mycobacterium tuberculosis et leurs utilisations
|
WO1999052708A1
(fr)
|
1998-04-13 |
1999-10-21 |
Luminex Corporation |
Marquage liquide a l'aide de microparticules fluorescentes
|
US7128927B1
(en)
|
1998-04-14 |
2006-10-31 |
Qlt Usa, Inc. |
Emulsions for in-situ delivery systems
|
US6406719B1
(en)
|
1998-05-13 |
2002-06-18 |
Microbiological Research Authority |
Encapsulation of bioactive agents
|
GB9810236D0
(en)
|
1998-05-13 |
1998-07-08 |
Microbiological Res Authority |
Improvements relating to encapsulation of bioactive agents
|
KR100293504B1
(ko)
|
1998-06-05 |
2001-07-12 |
김윤 |
서방형전립선염치료제조성물
|
JP2002524108A
(ja)
|
1998-07-28 |
2002-08-06 |
インナーダイン, インコーポレイテッド |
吸収性近接照射療法および化学療法送達デバイスならびに方法
|
CA2336523C
(fr)
|
1998-08-07 |
2015-06-30 |
University Of Washington |
Antigenes immunologiques de l'herpes simplex virus
|
US6013122A
(en)
*
|
1998-08-18 |
2000-01-11 |
Option Technologies, Inc. |
Tattoo inks
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
MY131835A
(en)
*
|
1998-11-20 |
2007-09-28 |
Gen Hospital Corp |
Permanent, removable tissue markings
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
TR200102500T2
(tr)
|
1998-12-08 |
2002-03-21 |
Corixa Corporation |
Chlamydia enfeksiyonunu tedavi etmek iin bileçikler.
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
YU72901A
(sh)
|
1999-04-02 |
2004-07-15 |
Corixa Corporation |
Preparati za primenu u terapiji i dijagnozi raka pluća
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
US6306425B1
(en)
|
1999-04-09 |
2001-10-23 |
Southern Research Institute |
Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
|
CA2386841A1
(fr)
*
|
1999-10-07 |
2001-04-12 |
Corixa Corporation |
Proteines hybrides de mycobacterium tuberculosis
|
US6458387B1
(en)
*
|
1999-10-18 |
2002-10-01 |
Epic Therapeutics, Inc. |
Sustained release microspheres
|
US20050037086A1
(en)
*
|
1999-11-19 |
2005-02-17 |
Zycos Inc., A Delaware Corporation |
Continuous-flow method for preparing microparticles
|
US6682754B2
(en)
*
|
1999-11-24 |
2004-01-27 |
Willmar Poultry Company, Inc. |
Ovo delivery of an immunogen containing implant
|
US6575888B2
(en)
|
2000-01-25 |
2003-06-10 |
Biosurface Engineering Technologies, Inc. |
Bioabsorbable brachytherapy device
|
EP1257257B1
(fr)
|
2000-02-17 |
2018-10-31 |
Neomend, Inc. |
Procédé de fabrication de systèmes d'administration utilisant des compositions polymères biodegradables préformées
|
CZ303468B6
(cs)
|
2000-02-23 |
2012-10-03 |
Smithkline Beecham Biologicals S. A. |
Imunogenní smes a farmaceutická smes
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20030175700A1
(en)
|
2000-04-21 |
2003-09-18 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
US20040142475A1
(en)
*
|
2000-06-02 |
2004-07-22 |
Barman Shikha P. |
Delivery systems for bioactive agents
|
DK1542732T3
(da)
|
2000-06-20 |
2009-12-14 |
Corixa Corp |
Fusionsproteiner af Mycobacterium tuberculosis
|
KR100392501B1
(ko)
*
|
2000-06-28 |
2003-07-22 |
동국제약 주식회사 |
다중 에멀젼법에 의한 서방출성 미립구의 제조방법
|
ATE396265T1
(de)
|
2000-06-28 |
2008-06-15 |
Corixa Corp |
Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
|
US20040158317A1
(en)
*
|
2000-07-18 |
2004-08-12 |
Pharmasonics, Inc. |
Coated stent with ultrasound therapy
|
US6479065B2
(en)
|
2000-08-10 |
2002-11-12 |
Alkermes Controlled Therapeutics, Inc. |
Process for the preparation of polymer-based sustained release compositions
|
US6296842B1
(en)
|
2000-08-10 |
2001-10-02 |
Alkermes Controlled Therapeutics, Inc. |
Process for the preparation of polymer-based sustained release compositions
|
US6824822B2
(en)
|
2001-08-31 |
2004-11-30 |
Alkermes Controlled Therapeutics Inc. Ii |
Residual solvent extraction method and microparticles produced thereby
|
US7374782B2
(en)
|
2000-10-27 |
2008-05-20 |
Baxter International Inc. |
Production of microspheres
|
US20040122090A1
(en)
*
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
AU2002232824A1
(en)
|
2000-12-21 |
2002-07-01 |
Inhale Therapeutic Systems, Inc. |
Induced phase transition method for the production of microparticles containing hydrophobic active agents
|
US20050203612A1
(en)
*
|
2000-12-22 |
2005-09-15 |
Avantec Vascular Corporation |
Devices delivering therapeutic agents and methods regarding the same
|
US20030050692A1
(en)
*
|
2000-12-22 |
2003-03-13 |
Avantec Vascular Corporation |
Delivery of therapeutic capable agents
|
US20030033007A1
(en)
*
|
2000-12-22 |
2003-02-13 |
Avantec Vascular Corporation |
Methods and devices for delivery of therapeutic capable agents with variable release profile
|
US20020082679A1
(en)
*
|
2000-12-22 |
2002-06-27 |
Avantec Vascular Corporation |
Delivery or therapeutic capable agents
|
US7077859B2
(en)
|
2000-12-22 |
2006-07-18 |
Avantec Vascular Corporation |
Apparatus and methods for variably controlled substance delivery from implanted prostheses
|
US6471980B2
(en)
|
2000-12-22 |
2002-10-29 |
Avantec Vascular Corporation |
Intravascular delivery of mycophenolic acid
|
US6939375B2
(en)
|
2000-12-22 |
2005-09-06 |
Avantac Vascular Corporation |
Apparatus and methods for controlled substance delivery from implanted prostheses
|
US20020082678A1
(en)
*
|
2000-12-22 |
2002-06-27 |
Motasim Sirhan |
Intravascular delivery of mizoribine
|
US7083642B2
(en)
|
2000-12-22 |
2006-08-01 |
Avantec Vascular Corporation |
Delivery of therapeutic capable agents
|
US7018405B2
(en)
|
2000-12-22 |
2006-03-28 |
Avantec Vascular Corporation |
Intravascular delivery of methylprednisolone
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
EP2706116A1
(fr)
|
2001-01-17 |
2014-03-12 |
Emergent Product Development Seattle, LLC |
Proteines de fusion d'immunoglobuline de domaine de liaison
|
US7618939B2
(en)
|
2001-02-15 |
2009-11-17 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to prevent cancer with cupredoxins
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
US6537195B2
(en)
|
2001-05-07 |
2003-03-25 |
Xoft, Microtube, Inc. |
Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
|
US7018371B2
(en)
*
|
2001-05-07 |
2006-03-28 |
Xoft, Inc. |
Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia
|
WO2002089747A2
(fr)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
|
CA2451187C
(fr)
|
2001-06-22 |
2012-08-14 |
Southern Biosystems, Inc. |
Implants coaxiaux a liberation prolongee d'ordre 0
|
JP2005514326A
(ja)
|
2001-07-10 |
2005-05-19 |
コリクサ コーポレイション |
ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
|
JP2005508671A
(ja)
*
|
2001-07-26 |
2005-04-07 |
アバンテク バスキュラー コーポレーション |
治療に有効な薬剤の送達
|
PT1418890E
(pt)
*
|
2001-08-16 |
2008-06-09 |
Baxter Int |
Formulações de micropartículas à base de propulsor
|
US20080026068A1
(en)
*
|
2001-08-16 |
2008-01-31 |
Baxter Healthcare S.A. |
Pulmonary delivery of spherical insulin microparticles
|
CA2460535A1
(fr)
|
2001-09-13 |
2003-03-20 |
Ansell Healthcare Products, Inc. |
Revetement a microcapsules pour gants
|
ES2606840T3
(es)
|
2001-10-10 |
2017-03-28 |
Ratiopharm Gmbh |
Remodelación y glicoconjugación de factor estimulante de colonias de granulocitos (G-CSF)
|
EP2292273A3
(fr)
|
2001-10-10 |
2011-11-23 |
BioGeneriX AG |
Remodelage et Glycoconjugaison de Peptides
|
WO2003049752A2
(fr)
|
2001-12-11 |
2003-06-19 |
Institut Pasteur |
Preparations a base de bacteries gram positif destinees au traitement de maladies presentant un dysfonctionnement immunitaire
|
DK1581119T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
ES2485841T3
(es)
|
2002-02-01 |
2014-08-14 |
Ariad Pharmaceuticals, Inc |
Compuestos que contienen fósforo y usos de los mismos
|
AU2003213118A1
(en)
*
|
2002-02-15 |
2003-09-09 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
US7157102B1
(en)
|
2002-05-31 |
2007-01-02 |
Biotek, Inc. |
Multi-layered microcapsules and method of preparing same
|
MXPA04011875A
(es)
*
|
2002-05-31 |
2005-03-31 |
Titan Pharmaceuticals Inc |
Dispositivo polimerico implantable para liberacion sostenida de buprenorfina.
|
US7041320B1
(en)
|
2002-05-31 |
2006-05-09 |
Biotek, Inc. |
High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
|
DE60335755D1
(de)
|
2002-07-18 |
2011-02-24 |
Univ Washington |
Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
|
US7736391B2
(en)
|
2003-02-06 |
2010-06-15 |
Tonaba Healthscience Ii, Llc |
Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis
|
EP2853593B1
(fr)
|
2003-03-07 |
2017-10-04 |
DSM IP Assets B.V. |
Hydrolases, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
|
US7803777B2
(en)
|
2003-03-14 |
2010-09-28 |
Biogenerix Ag |
Branched water-soluble polymers and their conjugates
|
MXPA05010450A
(es)
|
2003-03-31 |
2005-11-04 |
Titan Pharmaceuticals Inc |
Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
|
US20040254419A1
(en)
*
|
2003-04-08 |
2004-12-16 |
Xingwu Wang |
Therapeutic assembly
|
US20070010702A1
(en)
*
|
2003-04-08 |
2007-01-11 |
Xingwu Wang |
Medical device with low magnetic susceptibility
|
EP2055189A1
(fr)
|
2003-04-09 |
2009-05-06 |
Neose Technologies, Inc. |
Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes
|
CA2516107C
(fr)
|
2003-04-10 |
2013-12-24 |
Ehud Zeigerson |
Procede de production de microparticules a base d'emulsion
|
US20070207211A1
(en)
*
|
2003-04-10 |
2007-09-06 |
Pr Pharmaceuticals, Inc. |
Emulsion-based microparticles and methods for the production thereof
|
US20060193825A1
(en)
*
|
2003-04-29 |
2006-08-31 |
Praecis Phamaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US20050112087A1
(en)
*
|
2003-04-29 |
2005-05-26 |
Musso Gary F. |
Pharmaceutical formulations for sustained drug delivery
|
NZ544618A
(en)
|
2003-06-16 |
2009-02-28 |
Celltech R & D Inc |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
ES2625343T3
(es)
*
|
2003-07-15 |
2017-07-19 |
Evonik Corporation |
Método para la preparación de formulaciones de liberación controlada
|
US20070092452A1
(en)
*
|
2003-07-18 |
2007-04-26 |
Julia Rashba-Step |
Methods for fabrication, uses, compositions of inhalable spherical particles
|
US20050142205A1
(en)
*
|
2003-07-18 |
2005-06-30 |
Julia Rashba-Step |
Methods for encapsulating small spherical particles prepared by controlled phase separation
|
SG135204A1
(en)
*
|
2003-07-18 |
2007-09-28 |
Baxter Int |
Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
|
US20050048127A1
(en)
*
|
2003-07-22 |
2005-03-03 |
Larry Brown |
Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
|
JP5165240B2
(ja)
*
|
2003-07-23 |
2013-03-21 |
ピーアール ファーマシューティカルズ, インコーポレイテッド |
徐放組成物
|
US20070149496A1
(en)
*
|
2003-10-31 |
2007-06-28 |
Jack Tuszynski |
Water-soluble compound
|
WO2005051229A2
(fr)
*
|
2003-11-24 |
2005-06-09 |
Avantec Vascular Corporation |
Dispositifs et procedes d'administration d'agents therapeutiques
|
WO2005058937A2
(fr)
|
2003-12-12 |
2005-06-30 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epitope de lymphocyte t cytotoxique humain et son epitope agoniste issus du nombre non variable de sequences repetees en tandem de muc-1
|
TW200529890A
(en)
*
|
2004-02-10 |
2005-09-16 |
Takeda Pharmaceutical |
Sustained-release preparations
|
EP1715742A4
(fr)
|
2004-02-20 |
2009-06-17 |
Lifescape Biosciences Inc |
Compositions et methodes de regulation du sommeil
|
US20100030183A1
(en)
*
|
2004-03-19 |
2010-02-04 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using a coated balloon
|
US8431145B2
(en)
|
2004-03-19 |
2013-04-30 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
US20070027523A1
(en)
*
|
2004-03-19 |
2007-02-01 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using coated balloon
|
AU2005222719B2
(en)
*
|
2004-03-19 |
2011-03-24 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
US20050249667A1
(en)
*
|
2004-03-24 |
2005-11-10 |
Tuszynski Jack A |
Process for treating a biological organism
|
US7456254B2
(en)
*
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
EA200601904A1
(ru)
|
2004-04-15 |
2007-02-27 |
Алкермес, Инк. |
Система отсроченного высвобождения лекарственного средства на основе полимеров
|
US20050239723A1
(en)
*
|
2004-04-27 |
2005-10-27 |
Amin Avinash N |
Compositions and methods useful for treatment of acne
|
MXPA06012992A
(es)
*
|
2004-05-12 |
2007-02-12 |
Baxter Int |
Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
|
US8728525B2
(en)
*
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
EP1765294B1
(fr)
|
2004-05-12 |
2008-09-24 |
Baxter International Inc. |
Production et administration de microsphères d'acide nucléique
|
PT1758558E
(pt)
*
|
2004-05-12 |
2013-12-05 |
Baxter Healthcare Sa |
Microesferas contendo oligonucleótidos, sua utilização para o fabrico de um medicamento para o tratamento de diabetes do tipo 1
|
EP1766096B1
(fr)
|
2004-05-25 |
2013-01-02 |
Oregon Health and Science University |
Vaccination du virus de l'immunodeficience humaine (vih) utilisant des vecteurs de vaccin a base de hcmv
|
US7604978B2
(en)
|
2004-07-14 |
2009-10-20 |
Sequoia Sciences, Inc. |
Inhibition of biofilm formation
|
US20060264411A1
(en)
*
|
2005-05-20 |
2006-11-23 |
Eldridge Gary R |
Control of biofilm formation
|
US20060014285A1
(en)
*
|
2004-07-14 |
2006-01-19 |
Eldridge Gary R |
Methods and compositions for inhibiting biofilms
|
EP2199801B1
(fr)
|
2004-07-14 |
2013-05-29 |
The Regents of The University of California |
Biomarqueurs pour la détection précoce du cancer des ovaires
|
US9132116B2
(en)
*
|
2004-08-02 |
2015-09-15 |
Willowcroft Pharm Inc. |
Mast cell stabilizers to prevent or treat laminitis
|
CA2575988C
(fr)
*
|
2004-08-04 |
2014-02-18 |
Brookwood Pharmaceuticals, Inc. |
Procede de production de systemes d'administration, et systemes d'administration
|
US7612045B2
(en)
|
2004-09-14 |
2009-11-03 |
Sequoia Sciences, Inc. |
Compounds, compositions and methods for controlling biofilms and bacterial infections
|
CA2587084C
(fr)
|
2004-10-08 |
2019-07-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation de la valeur adaptative reproductive au moyen de codons synonymes employes moins frequemment
|
US7619007B2
(en)
*
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
DE05852057T1
(de)
|
2004-11-23 |
2007-11-29 |
Neuromolecular Pharmaceuticals Inc., Emeryville |
Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt
|
CA2588296A1
(fr)
|
2004-11-24 |
2006-06-01 |
Neuromolecular Pharmaceuticals, Inc. |
Composition et methode pour traiter des affections neurologiques
|
US20070150051A1
(en)
*
|
2005-01-10 |
2007-06-28 |
Duke Fiduciary, Llc |
Vascular implants and methods of fabricating the same
|
EP1858543B1
(fr)
|
2005-01-10 |
2013-11-27 |
BioGeneriX AG |
Facteur de stimulation de colonie de granulocytes glycopegylé
|
US8287583B2
(en)
*
|
2005-01-10 |
2012-10-16 |
Taheri Laduca Llc |
Apparatus and method for deploying an implantable device within the body
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
US9050393B2
(en)
*
|
2005-02-08 |
2015-06-09 |
Bruce N. Saffran |
Medical devices and methods for modulation of physiology using device-based surface chemistry
|
EP1701165A1
(fr)
|
2005-03-07 |
2006-09-13 |
Johannes Dr. Coy |
Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs
|
BRPI0609547A2
(pt)
|
2005-03-31 |
2011-10-18 |
Glaxosmithkline Biolog Sa |
composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
|
KR101406456B1
(ko)
|
2005-04-06 |
2014-06-20 |
아다마스 파마슈티칼스, 인코포레이티드 |
Cns 장애의 치료를 위한 방법 및 조성물
|
US20060228384A1
(en)
*
|
2005-04-06 |
2006-10-12 |
Sequoia Sciences, Inc. |
Control of biofilm with a biofilm inhibitor
|
WO2006121569A2
(fr)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions et methodes utilisees pour la preparation de mutants par glycosylation de l'hormone de croissance humaine resistant a la protease
|
CN101188996B
(zh)
*
|
2005-04-27 |
2013-03-27 |
巴克斯特国际公司 |
表面改性的微粒及其形成和使用方法
|
CA2607715C
(fr)
|
2005-04-29 |
2015-11-24 |
Glaxosmithkline Biologicals S.A. |
Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis
|
US7968694B2
(en)
|
2005-07-01 |
2011-06-28 |
Forsyth Dental Infirmary For Children |
Tuberculosis antigen detection assays and vaccines
|
KR100741867B1
(ko)
*
|
2005-07-05 |
2007-07-24 |
전북대학교산학협력단 |
수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
|
US20070014739A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Eldridge Gary R |
Compositions and methods for controlling biofilms and bacterial infections
|
US7462698B2
(en)
*
|
2005-07-22 |
2008-12-09 |
Y's Therapeutics Co., Ltd. |
Anti-CD26 antibodies and methods of use thereof
|
ES2539250T3
(es)
|
2005-07-25 |
2015-06-29 |
Emergent Product Development Seattle, Llc |
Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
|
US20090099031A1
(en)
*
|
2005-09-27 |
2009-04-16 |
Stemmer Willem P |
Genetic package and uses thereof
|
CA2622441A1
(fr)
*
|
2005-09-27 |
2007-04-05 |
Amunix, Inc. |
Produits pharmaceutiques proteiques et utilisations de ceux-ci
|
US7855279B2
(en)
*
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
ES2755032T3
(es)
*
|
2005-12-22 |
2020-04-21 |
Novartis Ag |
Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido
|
EP2918283B1
(fr)
|
2005-12-30 |
2018-01-31 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Libération prolongée de la neuréguline destinée à améliorer la fonction cardiaque
|
WO2007079755A1
(fr)
|
2006-01-12 |
2007-07-19 |
Janus Beierholm Holding Aps |
Ré-immunisation et conception d'anticorps
|
WO2007082105A2
(fr)
|
2006-01-16 |
2007-07-19 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vaccin contre chlamydia
|
WO2007092314A2
(fr)
|
2006-02-02 |
2007-08-16 |
Verenium Corporation |
Estérases, acides nucléiques apparentés et procédés associés
|
US8921050B2
(en)
|
2006-03-17 |
2014-12-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of diagnosing renal cell carcinoma
|
US8524454B2
(en)
|
2006-04-07 |
2013-09-03 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
DK2027158T3
(da)
|
2006-05-02 |
2013-01-14 |
Carviar Aps |
Metode til immunisering af en fugleart
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
US20070281031A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Guohan Yang |
Microparticles and methods for production thereof
|
US20090258028A1
(en)
*
|
2006-06-05 |
2009-10-15 |
Abbott Cardiovascular Systems Inc. |
Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
|
US8323676B2
(en)
*
|
2008-06-30 |
2012-12-04 |
Abbott Cardiovascular Systems Inc. |
Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
|
CA2654317A1
(fr)
*
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur
|
US8017237B2
(en)
|
2006-06-23 |
2011-09-13 |
Abbott Cardiovascular Systems, Inc. |
Nanoshells on polymers
|
US7964574B2
(en)
|
2006-08-04 |
2011-06-21 |
Baxter International Inc. |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
EP2359808B1
(fr)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Système de libération osmotique avec ensemble de piston
|
ES2387327T3
(es)
|
2006-09-26 |
2012-09-20 |
Infectious Disease Research Institute |
Composición de vacuna que contiene un adyuvante sintético
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
WO2008060780A2
(fr)
|
2006-10-04 |
2008-05-22 |
Novo Nordisk A/S |
Glycopeptides et sucres pégylés à liaison glycérol
|
EP2068845A2
(fr)
*
|
2006-10-06 |
2009-06-17 |
Baxter International Inc. |
Microcapsules contenant des microparticules modifiées en surface et leurs procédés de formation et d'utilisation
|
EP2114303A4
(fr)
|
2007-02-09 |
2012-08-08 |
Taheri Laduca Llc |
Implants vasculaires et procédés de fabrication desdits implants
|
US8808747B2
(en)
*
|
2007-04-17 |
2014-08-19 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
EA019284B1
(ru)
*
|
2007-06-06 |
2014-02-28 |
Дебиофарм Рисёрч Энд Мэньюфэкчуринг Са |
Фармацевтическая композиция с пролонгированным высвобождением, приготовленная из микрочастиц
|
EP2167130A2
(fr)
*
|
2007-07-06 |
2010-03-31 |
Trubion Pharmaceuticals, Inc. |
Peptides de liaison comprenant un domaine de liaison spécifique c-terminal
|
WO2009023270A2
(fr)
*
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions et procédés d'amélioration de la production de polypeptides recombinés
|
US20110172305A1
(en)
*
|
2007-10-02 |
2011-07-14 |
Ester Fride |
Endocannabinoids for Enhancing Growth and Development in Infants
|
US8932558B2
(en)
*
|
2007-10-05 |
2015-01-13 |
Plaxgen Inc |
Multi-subunit biological complexes for treatment of plaque-associated diseases
|
US7828840B2
(en)
*
|
2007-11-15 |
2010-11-09 |
Med Institute, Inc. |
Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
|
EP2222284B1
(fr)
*
|
2007-11-19 |
2020-07-01 |
Capsulated Systems Inc. |
Libération prolongée d'anesthésiques locaux au moyen de microparticules et applications chirurgicales
|
US8619257B2
(en)
|
2007-12-13 |
2013-12-31 |
Kimberley-Clark Worldwide, Inc. |
Recombinant bacteriophage for detection of nosocomial infection
|
US8728528B2
(en)
|
2007-12-20 |
2014-05-20 |
Evonik Corporation |
Process for preparing microparticles having a low residual solvent volume
|
EP2240155B1
(fr)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
|
WO2009126306A2
(fr)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions et procédés pour la détection des mutations d’egfr en cas de cancer
|
CN105198997B
(zh)
*
|
2008-04-11 |
2018-08-31 |
阿普拜佛研发有限责任公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
AU2009237577B2
(en)
|
2008-04-18 |
2014-06-05 |
Baxter Healthcare Sa |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
EP2123748A1
(fr)
|
2008-05-20 |
2009-11-25 |
Institut Pasteur |
2'-5'-oligoadénylate synthétase 3 pour prévenir et traiter une infection par virus à ARN à brin unique de sens positif
|
US8765162B2
(en)
|
2008-06-30 |
2014-07-01 |
Abbott Cardiovascular Systems Inc. |
Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
|
US8323615B2
(en)
*
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing multi-phasic dispersions
|
US20100047292A1
(en)
*
|
2008-08-20 |
2010-02-25 |
Baxter International Inc. |
Methods of processing microparticles and compositions produced thereby
|
US8367427B2
(en)
*
|
2008-08-20 |
2013-02-05 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
US8323685B2
(en)
*
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
US8153391B2
(en)
|
2008-08-29 |
2012-04-10 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8357503B2
(en)
|
2008-08-29 |
2013-01-22 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8198062B2
(en)
|
2008-08-29 |
2012-06-12 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
EP2344447B1
(fr)
|
2008-10-08 |
2016-06-08 |
Xgene Pharmaceutical Inc |
Conjugués gaba et procédés d'utilisation de ceux-ci
|
US20100216948A1
(en)
*
|
2009-01-23 |
2010-08-26 |
Tipton Arthur J |
Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
|
WO2010085609A2
(fr)
*
|
2009-01-23 |
2010-07-29 |
Surmodics Pharmaceuticals, Inc. |
Système à libération contrôlée de mélange polymères
|
CN116925238A
(zh)
|
2009-02-03 |
2023-10-24 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
PL2418945T3
(pl)
|
2009-04-15 |
2019-05-31 |
Bmg Pharma S P A |
Kompozycje soli mineralnej - kwasu sulfonowego i sposoby ich stosowania
|
AU2010256461B2
(en)
|
2009-06-05 |
2016-03-17 |
Access To Advanced Health Institute |
Synthetic glucopyranosyl lipid adjuvants
|
US20110038852A1
(en)
*
|
2009-06-10 |
2011-02-17 |
3-V Biosciences, Inc. |
Antivirals that target transporters, carriers, and ion channels
|
US8911766B2
(en)
*
|
2009-06-26 |
2014-12-16 |
Abbott Cardiovascular Systems Inc. |
Drug delivery compositions including nanoshells for triggered drug release
|
EP2292260A1
(fr)
|
2009-08-13 |
2011-03-09 |
Institut Pasteur |
Utilisation de mycobactérie bois tuée par lyophilisation étendue pour la prévention ou le traitement de l'athérosclérose
|
CA2772051C
(fr)
|
2009-08-24 |
2020-08-18 |
Amunix Operating Inc. |
Compositions de facteur ix de coagulation et leurs procedes de fabrication et d'utilisation
|
WO2011034950A1
(fr)
|
2009-09-16 |
2011-03-24 |
Vaxart, Inc. |
Stratégie d'immunisation pour empêcher une infection par le h1n1
|
CA2774495C
(fr)
*
|
2009-09-17 |
2017-09-26 |
Evonik Degussa Corporation |
Dispositifs d'implant dont les profils de liberation different et procedes de fabrication et d'utilisation de ceux-ci
|
RU2545865C2
(ru)
*
|
2009-09-22 |
2015-04-10 |
Евоник Корпорейшн |
Имплантируемые устройства с различными вариантами загрузки биологически активного компонента
|
EP3323423B1
(fr)
|
2009-09-28 |
2020-06-17 |
Intarcia Therapeutics, Inc |
Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament
|
CN102781259A
(zh)
|
2009-09-30 |
2012-11-14 |
加利福尼亚大学董事会 |
辅因子及个体使用方法
|
WO2011053675A2
(fr)
|
2009-10-30 |
2011-05-05 |
Cns Therapeutics, Inc. |
Molécules de neurturine améliorées
|
US20110104138A1
(en)
|
2009-11-03 |
2011-05-05 |
Institut Pasteur |
Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
|
EP3461889A1
(fr)
|
2009-11-19 |
2019-04-03 |
Solis Biodyne |
Compositions permettant d'augmenter la stabilité et l'activité de polypeptides et procédés associés
|
MX2012006320A
(es)
|
2009-12-02 |
2013-01-18 |
Adamas Pharmaceuticals Inc |
Composiciones de amantadina y metodos para su uso.
|
US20110144577A1
(en)
*
|
2009-12-11 |
2011-06-16 |
John Stankus |
Hydrophilic coatings with tunable composition for drug coated balloon
|
US8480620B2
(en)
*
|
2009-12-11 |
2013-07-09 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable solubility profile for drug-coated balloon
|
US8951595B2
(en)
*
|
2009-12-11 |
2015-02-10 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable molecular architecture for drug-coated balloon
|
KR20130088002A
(ko)
|
2010-01-13 |
2013-08-07 |
재단법인 한국파스퇴르연구소 |
항-감염성 피리도(1,2-a)피리미딘
|
HUE031184T2
(en)
|
2010-01-27 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Modified tuberculosis antigens
|
WO2011116396A2
(fr)
|
2010-03-19 |
2011-09-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Fragments de facteur de croissance d'hépatocyte qui fonctionnent comme agonistes et antagonistes du récepteur met puissant
|
US9295663B2
(en)
|
2010-07-14 |
2016-03-29 |
Abbott Cardiovascular Systems Inc. |
Drug coated balloon with in-situ formed drug containing microspheres
|
DK2601609T3
(en)
|
2010-08-02 |
2017-06-06 |
Population Bio Inc |
COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS
|
CA2816883A1
(fr)
|
2010-11-23 |
2012-05-31 |
Presage Biosciences, Inc. |
Procedes et compositions therapeutiques pour administration de solide
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
KR101930106B1
(ko)
|
2011-03-08 |
2018-12-17 |
3-브이 바이오사이언시스, 인코포레이티드 |
지질 합성의 헤테로사이클릭 조절자
|
DK2683736T3
(en)
|
2011-03-09 |
2018-04-23 |
Cell Signaling Technology Inc |
METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
|
CN103596586A
(zh)
|
2011-04-08 |
2014-02-19 |
免疫设计公司 |
免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
|
EP2720706B1
(fr)
|
2011-06-17 |
2020-08-05 |
University of Tennessee Research Foundation |
Vaccin multivalent contre un streptocoque du groupe a
|
WO2012177595A1
(fr)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions et méthodes pour la thérapie et le diagnostic du cancer
|
AU2012284267B2
(en)
|
2011-07-15 |
2017-06-29 |
Nusirt Sciences, Inc. |
Compositions and methods for modulating metabolic pathways
|
US8324264B1
(en)
|
2011-07-22 |
2012-12-04 |
Sequoia Sciences, Inc. |
Inhibitors of bacterial biofilms and related methods
|
EP2766483B1
(fr)
|
2011-10-10 |
2022-03-23 |
The Hospital For Sick Children |
Méthodes et compositions de dépistage et de traitement de troubles du développement
|
SG11201401851UA
(en)
|
2011-10-28 |
2014-05-29 |
Presage Biosciences Inc |
Methods for drug delivery
|
WO2013067451A2
(fr)
|
2011-11-04 |
2013-05-10 |
Population Diagnostics Inc. |
Méthodes et compositions pour le diagnostic, le pronostic et le traitement d'états neurologiques
|
KR102134932B1
(ko)
|
2011-11-11 |
2020-07-17 |
프레드 헛친슨 켄서 리서치 센터 |
암을 위한 사이클린 a1―표적화된 t―세포 면역요법
|
EP2811981B1
(fr)
|
2012-02-07 |
2019-05-08 |
Infectious Disease Research Institute |
Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
|
EP2812452B1
(fr)
|
2012-02-09 |
2020-05-27 |
Population Bio, Inc. |
Méthodes et compositions permettant de rechercher et de traiter des troubles du développement
|
LT2822577T
(lt)
|
2012-02-15 |
2019-03-25 |
Bioverativ Therapeutics Inc. |
Rekombinantiniai faktoriaus viii baltymai
|
ES2935489T3
(es)
|
2012-02-15 |
2023-03-07 |
Bioverativ Therapeutics Inc |
Composiciones de factor VIII y métodos de preparación y uso de las mismas
|
CN108771687A
(zh)
|
2012-02-29 |
2018-11-09 |
伊西康内外科公司 |
微生物区系的组合物及与其相关的方法
|
US9198454B2
(en)
|
2012-03-08 |
2015-12-01 |
Nusirt Sciences, Inc. |
Compositions, methods, and kits for regulating energy metabolism
|
WO2013134577A2
(fr)
|
2012-03-08 |
2013-09-12 |
Detectogen, Inc. |
Dosages de détection d'antigène de leishmaniose et vaccins
|
DK2850431T3
(en)
|
2012-05-16 |
2018-07-16 |
Immune Design Corp |
Vaccines against HSV-2
|
DK2895621T3
(da)
|
2012-09-14 |
2020-11-30 |
Population Bio Inc |
Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
|
WO2014052855A1
(fr)
|
2012-09-27 |
2014-04-03 |
Population Diagnostics, Inc. |
Procédés et compositions de dépistage et de traitement de troubles du développement
|
CN108452311A
(zh)
|
2012-11-13 |
2018-08-28 |
纽斯尔特科学公司 |
用于增强能量代谢的组合物和方法
|
WO2014113404A1
(fr)
|
2013-01-15 |
2014-07-24 |
Nusirt Sciences, Inc. |
Traitement de maladies pulmonaires
|
SG11201507046UA
(en)
|
2013-03-15 |
2015-10-29 |
Nusirt Sciences Inc |
Leucine and nicotinic acid reduces lipid levels
|
EP3711768A1
(fr)
|
2013-04-18 |
2020-09-23 |
Immune Design Corp. |
Monothérapie de gla destinée à être utilisée dans le traitement du cancer
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
WO2014204933A1
(fr)
|
2013-06-17 |
2014-12-24 |
Adamas Pharmaceuticals, Inc. |
Compositions d'amantadine et procédés d'utilisation
|
WO2014210546A1
(fr)
|
2013-06-27 |
2014-12-31 |
University Of Washington Through Its Center For Commercialization |
Système polymère biocompatible pour le traitement ciblé de troubles thrombotiques et hémostatiques
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
US10633714B2
(en)
|
2013-07-21 |
2020-04-28 |
Pendulum Therapeutics, Inc. |
Methods and systems for microbiome characterization, monitoring and treatment
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
ES2841137T3
(es)
|
2013-12-20 |
2021-07-07 |
Sagimet Biosciences Inc |
Moduladores heterocíclicos de la síntesis de lípidos y combinaciones de los mismos
|
MX2016008841A
(es)
|
2014-01-07 |
2016-10-13 |
3-V Biosciences Inc |
Moduladores heterociclicos de la sintesis de lipidos para su uso contra el cancer e infecciones virales.
|
MA39228A1
(fr)
|
2014-01-21 |
2017-06-30 |
Immune Design Corp |
Compositions à utiliser pour le traitement d'états allergiques
|
KR102396817B1
(ko)
|
2014-02-20 |
2022-05-11 |
박사르트, 인크. |
소장 전달을 위한 제형들
|
KR20160119863A
(ko)
|
2014-02-27 |
2016-10-14 |
뉴서트 사이언시스, 인크. |
간 지방증의 감소 또는 예방을 위한 조성물 및 방법
|
JP6737714B2
(ja)
|
2014-03-14 |
2020-08-12 |
ユニヴァーシティ オブ ワシントン |
ゲノムインスレーターエレメントおよびその使用
|
CN113403338A
(zh)
|
2014-03-28 |
2021-09-17 |
华盛顿大学商业中心 |
乳腺癌和卵巢癌疫苗
|
EP3169699A4
(fr)
|
2014-07-18 |
2018-06-20 |
The University of Washington |
Compositions de vaccin anticancéreux et leurs méthodes d'utilisation
|
US10724096B2
(en)
|
2014-09-05 |
2020-07-28 |
Population Bio, Inc. |
Methods and compositions for inhibiting and treating neurological conditions
|
WO2016054240A1
(fr)
|
2014-09-30 |
2016-04-07 |
Sean Dalziel |
Combinaisons à dose fixe pour le traitement de maladies virales
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
CA2964467A1
(fr)
|
2014-10-14 |
2016-04-21 |
Research Development Foundation |
Procede de generation d'enzymes genetiquement modifiees
|
EP3881680A1
(fr)
|
2014-10-31 |
2021-09-22 |
Pendulum Therapeutics, Inc. |
Procédés et compositions se rapportant à un traitement microbien de troubles
|
EP3277675B1
(fr)
|
2015-03-19 |
2022-01-19 |
Sagimet Biosciences Inc. |
Modulateurs hétérocycles de la synthèse des lipides
|
EP3307239B1
(fr)
|
2015-06-12 |
2020-09-16 |
Vaxart, Inc. |
Formulations pour l'administration dans l'intestin grêle d'antigènes du rsv et des norovirus
|
TWI741992B
(zh)
|
2015-08-03 |
2021-10-11 |
美商百歐維拉提夫治療公司 |
因子ix融合蛋白以及其製備及使用方法
|
BR112018005573A2
(pt)
|
2015-09-21 |
2019-01-22 |
Aptevo Research And Development Llc |
?polipeptídeos de ligação a cd3?
|
US20190169262A1
(en)
|
2015-12-04 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Slc45a2 peptides for immunotherapy
|
BR112018012870A2
(pt)
|
2015-12-30 |
2018-12-04 |
Adamas Pharmaceuticals Inc |
métodos e composições para o tratamento de transtornos relacionados à crise
|
CN109415445A
(zh)
|
2016-05-04 |
2019-03-01 |
阿比利塔生物公司 |
用于制备多跨膜蛋白的方法和平台
|
KR20240037175A
(ko)
|
2016-05-16 |
2024-03-21 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
RU2761870C2
(ru)
|
2016-05-16 |
2021-12-13 |
Инфекшес Дизис Рисёрч Инститьют |
Состав, содержащий агонист tlr, и способы применения
|
EP3458028A1
(fr)
|
2016-05-16 |
2019-03-27 |
Infectious Disease Research Institute |
Liposomes pégylés et procédés d'utilisation
|
EP3463300A1
(fr)
|
2016-06-01 |
2019-04-10 |
Infectious Disease Research Institute |
Nanoparticules d'alun contenant un agent d'encollage
|
US11725232B2
(en)
|
2016-10-31 |
2023-08-15 |
The Hong Kong University Of Science And Technology |
Compositions, methods and kits for detection of genetic variants for alzheimer's disease
|
IL307966A
(en)
|
2017-01-03 |
2023-12-01 |
Intarcia Therapeutics Inc |
Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
US11678967B2
(en)
|
2017-02-28 |
2023-06-20 |
Provasctec Limited |
Intravascular cell therapy device
|
WO2018200885A1
(fr)
|
2017-04-26 |
2018-11-01 |
Neurocentria, Inc. |
Compositions de magnésium et méthodes d'utilisation
|
US20200115324A1
(en)
|
2017-06-11 |
2020-04-16 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
KR20200028395A
(ko)
|
2017-06-15 |
2020-03-16 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
EP3675882A4
(fr)
|
2017-08-30 |
2021-07-28 |
Pendulum Therapeutics, Inc. |
Methodes et compositions pour le traitement de troubles associés au microbiome
|
CN110123789A
(zh)
*
|
2018-02-02 |
2019-08-16 |
山东墨海生物科技有限公司 |
一种载利培酮的plga微球混合物及其制备方法
|
CN112119092A
(zh)
|
2018-02-12 |
2020-12-22 |
无糖尿病公司 |
改进的拮抗性抗人cd40单克隆抗体
|
KR20240014102A
(ko)
|
2018-06-29 |
2024-01-31 |
우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 |
레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
|
SI3625368T1
(sl)
|
2018-08-08 |
2023-04-28 |
Pml Screening, Llc |
Postopki z genetskim testiranjem za oceno tveganja za razvoj progresivne multifokalne levkoencefalopatije, ki jo povzroča virus John Cunningham
|
EP3840785A4
(fr)
|
2018-08-20 |
2022-07-13 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions et méthodes de traitement de la neuropathie optique héréditaire de leber
|
CN111315407B
(zh)
|
2018-09-11 |
2023-05-02 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
WO2020067887A1
(fr)
|
2018-09-24 |
2020-04-02 |
Erasmus University Medical Center Rotterdam |
Inhibition spécifique de la janus kinase 3 (jak3) pour moduler des réponses immunitaires antitumorales
|
WO2020102454A1
(fr)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Peptides ciblant le cd40 et leurs utilisations
|
EP4013788A1
(fr)
|
2019-08-12 |
2022-06-22 |
Purinomia Biotech, Inc. |
Méthodes et compositions pour favoriser et potentialiser des réponses immunitaires à médiation par des lymphocytes t par ciblage adcc de cellules exprimant cd39
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
CN113025633A
(zh)
|
2019-12-09 |
2021-06-25 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
CA3178726A1
(fr)
|
2020-05-21 |
2021-11-25 |
Gregory LIZEE |
Recepteurs de lymphocytes t ayant une specificite pour le vgll1 et leurs utilisations
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
US20230310323A1
(en)
|
2020-09-04 |
2023-10-05 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
CA3173951A1
(fr)
|
2020-09-04 |
2022-03-10 |
Emily VOIGT |
Vaccins a base d'arn a adjuvant genetique
|
WO2022051023A1
(fr)
|
2020-09-04 |
2022-03-10 |
Infectious Disease Research Institute |
Technologie de vaccin hybride à arn atténué vivant
|
WO2022234003A1
(fr)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Polypeptides se liant à cd33 avec protéine stefin a
|
CN115927472A
(zh)
|
2021-07-05 |
2023-04-07 |
武汉纽福斯生物科技有限公司 |
一种抗vegf抗体体内表达系统的构建和应用
|
AR126727A1
(es)
|
2021-08-06 |
2023-11-08 |
Wuhan Neurophth Biotechnology Ltd Company |
Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4
|
TW202332694A
(zh)
|
2021-10-07 |
2023-08-16 |
英商阿凡克塔生命科學公司 |
血清半衰期延長之pd-l1結合多肽
|
WO2023057567A1
(fr)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Affimers de liaison à pd-l1
|
WO2023218243A1
(fr)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Protéines de fusion de liaison lag-3/pd-l1
|
WO2024052882A1
(fr)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Composition de vaccin immunogène incorporant une saponine
|